Spruce Street Capital LP — 13F Holdings & Portfolio
CIK 2050194 · latest 13F-HR filed 2026-08-13
Spruce Street Capital LP manages $509.7M in 13F-reported U.S. long-equity assets across 30 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are KNSA (11.52%), RLAY (10.95%), LBRX (8.76%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 5 new positions, exited 3, added to 16, and trimmed 5.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
SUITE 1704
NEW YORK, NY 10017
$509.7M
Long-equity book
30
Distinct positions
2026-06-30
Filed 2026-08-13
+5 / −3 / ↑16 / ↓5
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- RELAY THERAPEUTICS INC$26.1M +88.0%
- KINIKSA PHARMACEUTICALS INTL$22.1M +60.2%
- ALKERMES PLC$17.3M +153.4%
- LB PHARMACEUTICALS INC$11.0M +32.7%
- ALTO NEUROSCIENCE INC$6.6M +22.6%
Top Trims
- SURROZEN INC-$1.4M -10.9%
- LEXEO THERAPEUTICS INC-$1.0M -18.9%
- MINERVA NEUROSCIENCES INC-$786.4K -7.9%
- ALECTOR INC-$294.1K -6.5%
- LEONABIO INC-$226.8K -5.9%
New Positions
- INFLARX NV$12.0M
- RESEARCH ALLIANCE CORP III$5.3M
- ZAI LAB LTD$5.3M
- ACHIEVE LIFE SCIENCE INC$4.8M
- JATT II ACQUISITION CORP$1.8M
Exited Positions
- CENTESSA PHARMACEUTICALS$19.5M
- KALVISTA PHARMACEUTICALS$18.1M
- MAZE THERAPEUTICS INC$6.0M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | KINIKSA PHARMACEUTICALS INTL | KNSA | G52694109 | $58.7M | 11.52% | 918,070 | SH |
| 2 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $55.8M | 10.95% | 2,984,125 | SH |
| 3 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $44.7M | 8.76% | 1,376,159 | SH |
| 4 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $44.2M | 8.68% | 6,391,328 | SH |
| 5 | ALTO NEUROSCIENCE INC | ANRO | 02157Q109 | $35.7M | 7.01% | 1,353,047 | SH |
| 6 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $34.6M | 6.79% | 354,816 | SH |
| 7 | ALKERMES PLC | ALKS | G01767105 | $28.5M | 5.59% | 543,876 | SH |
| 8 | SAVARA INC | SVRA | 805111101 | $21.3M | 4.17% | 3,452,576 | SH |
| 9 | VAXCYTE INC | PCVX | 92243G108 | $17.8M | 3.49% | 306,047 | SH |
| 10 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $16.7M | 3.28% | 329,006 | SH |
| 11 | ENANTA PHARMACEUTICALS INC | ENTA | 29251M106 | $15.9M | 3.11% | 1,088,731 | SH |
| 12 | PERSPECTIVE THERAPEUTICS INC | CATX | 46489V302 | $12.6M | 2.47% | 3,693,931 | SH |
| 13 | INFLARX NV | IFRX | N44821101 | $12.0M | 2.35% | 5,352,198 | SH |
| 14 | SURROZEN INC | SRZN | 86889P208 | $11.2M | 2.20% | 432,040 | SH |
| 15 | ALUMIS INC | ALMS | 022307102 | $11.0M | 2.17% | 392,574 | SH |
| 16 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $9.9M | 1.95% | 4,059,054 | SH |
| 17 | MINERVA NEUROSCIENCES INC | NERV | 603380205 | $9.2M | 1.80% | 1,655,500 | SH |
| 18 | SAB BIOTHERAPEUTICS INC | SABS | 78397T202 | $8.6M | 1.68% | 2,198,502 | SH |
| 19 | AN2 THERAPEUTICS INC | ANTX | 037326105 | $8.0M | 1.58% | 1,661,073 | SH |
| 20 | ERASCA INC | ERAS | 29479A108 | $7.7M | 1.52% | 422,543 | SH |
| 21 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $7.3M | 1.43% | 3,581,603 | SH |
| 22 | RESEARCH ALLIANCE CORP III | RACC | G75226103 | $5.3M | 1.05% | 500,000 | SH |
| 23 | HELIX ACQUISITION CORP III | HLXC | G4444S107 | $5.3M | 1.04% | 500,000 | SH |
| 24 | ZAI LAB LTD | ZLAB | 98887Q104 | $5.3M | 1.04% | 279,110 | SH |
| 25 | ACHIEVE LIFE SCIENCE INC | ACHV | 004468500 | $4.8M | 0.94% | 736,637 | SH |
| 26 | LEXEO THERAPEUTICS INC | LXEO | 52886X107 | $4.3M | 0.85% | 928,593 | SH |
| 27 | ALECTOR INC | ALEC | 014442107 | $4.2M | 0.83% | 2,101,068 | SH |
| 28 | LEONABIO INC | LONA | 04746L203 | $3.6M | 0.71% | 393,701 | SH |
| 29 | CORVUS PHARMACEUTICALS INC | CRVS | 221015100 | $3.5M | 0.68% | 231,585 | SH |
| 30 | JATT II ACQUISITION CORP | JATT | G50765109 | $1.8M | 0.36% | 160,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | $509.7M | 30 | 0002050194-26-000005 |
| 2026-03-31 | 2026-05-14 | $415.9M | 28 | 0002050194-26-000004 |
| 2025-12-31 | 2026-02-13 | $302.7M | 27 | 0002050194-26-000001 |